Cargando…
Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma
PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitativ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885771/ https://www.ncbi.nlm.nih.gov/pubmed/36727035 http://dx.doi.org/10.2147/JHC.S390820 |
_version_ | 1784879998813863936 |
---|---|
author | Yang, Xue Chang, Jing Li, Ruili Qi, Yu Zeng, Xufen Wang, Wei Li, Hongjun |
author_facet | Yang, Xue Chang, Jing Li, Ruili Qi, Yu Zeng, Xufen Wang, Wei Li, Hongjun |
author_sort | Yang, Xue |
collection | PubMed |
description | PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitatively evaluated the hypovascular component in tumor and qualitatively assessed LI-RADS features and other aggressive features to develop model for cHCC-CCA diagnose. Subgroup analyses were performed by tumor size and LI-RADS category. RESULTS: cHCC-CCA frequently showed a larger proportion (≥50%) of hypovascular areas followed by HCC (P = 0.000). Among those patients with ≥50% hypovascular areas, 8 patients did not present rim enhancement in atrial phase. The LI-RADS major features were more commonly observed in HCC (82.9–45.7%,), than cHCC-CCA (P = 0.003–0.022). The targetoid appearances and non-smooth margin frequently appeared in cHCC-CCA (34.3–63.9%), compared with HCC (P = 0.000–0.023). We developed a radiologic model based on ≥50% hypovascular component and delayed enhancement, which presented AUC of 0.821, accuracy of 80%. We also obtained good performance by radiologic model in LR-M group and tumor size <50mm group (AUC: 0.841 and 0.866, respectively). Combined group which included CA 19–9 and ≥50% hypovascular component and delayed enhancement did not improve the distinction performance between cHCC-CCA and HCC, which presented good performance of identifying cHCC-CCA in the LR-4/5 subgroup and tumor size ≥50 mm subgroup (AUC: 0.717, 0.730, respectively). cHCC-CCA group presented heterogeneous dominant pathology involving 15 of HCC, 7 of intrahepatic cholangiocarcinoma (iCCA) or cholangiolocellular carcinoma (CLC), 13 of intermediate cells component. Macrotrabecular appearances were higher in cHCC-CCA than that in HCC. The proportion of Hepa-1 was significantly higher in true negative (TN) patients (29 [93.5%]) and false negative (FN) patients (10 [100%]) than in true positive (TP) patients (16 [64%]; P = 0.036). CONCLUSION: Quantitative assessment of hypovascular component could help the discrimination of cHCC-CCA. Macrotrabecular appearances were more exhibited in cHCC-CCA than that in HCC. |
format | Online Article Text |
id | pubmed-9885771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98857712023-01-31 Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Yang, Xue Chang, Jing Li, Ruili Qi, Yu Zeng, Xufen Wang, Wei Li, Hongjun J Hepatocell Carcinoma Original Research PURPOSE: To explore the imaging performance for discrimination of combined hepatocellular- cholangiocarcinoma (cHCC-CCA) and hepatocellular carcinoma (HCC). METHODS: In total, 35 patients with cHCC-CCA and a matched control group of HCC patients (n = 35) were included retrospectively. We quantitatively evaluated the hypovascular component in tumor and qualitatively assessed LI-RADS features and other aggressive features to develop model for cHCC-CCA diagnose. Subgroup analyses were performed by tumor size and LI-RADS category. RESULTS: cHCC-CCA frequently showed a larger proportion (≥50%) of hypovascular areas followed by HCC (P = 0.000). Among those patients with ≥50% hypovascular areas, 8 patients did not present rim enhancement in atrial phase. The LI-RADS major features were more commonly observed in HCC (82.9–45.7%,), than cHCC-CCA (P = 0.003–0.022). The targetoid appearances and non-smooth margin frequently appeared in cHCC-CCA (34.3–63.9%), compared with HCC (P = 0.000–0.023). We developed a radiologic model based on ≥50% hypovascular component and delayed enhancement, which presented AUC of 0.821, accuracy of 80%. We also obtained good performance by radiologic model in LR-M group and tumor size <50mm group (AUC: 0.841 and 0.866, respectively). Combined group which included CA 19–9 and ≥50% hypovascular component and delayed enhancement did not improve the distinction performance between cHCC-CCA and HCC, which presented good performance of identifying cHCC-CCA in the LR-4/5 subgroup and tumor size ≥50 mm subgroup (AUC: 0.717, 0.730, respectively). cHCC-CCA group presented heterogeneous dominant pathology involving 15 of HCC, 7 of intrahepatic cholangiocarcinoma (iCCA) or cholangiolocellular carcinoma (CLC), 13 of intermediate cells component. Macrotrabecular appearances were higher in cHCC-CCA than that in HCC. The proportion of Hepa-1 was significantly higher in true negative (TN) patients (29 [93.5%]) and false negative (FN) patients (10 [100%]) than in true positive (TP) patients (16 [64%]; P = 0.036). CONCLUSION: Quantitative assessment of hypovascular component could help the discrimination of cHCC-CCA. Macrotrabecular appearances were more exhibited in cHCC-CCA than that in HCC. Dove 2023-01-26 /pmc/articles/PMC9885771/ /pubmed/36727035 http://dx.doi.org/10.2147/JHC.S390820 Text en © 2023 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yang, Xue Chang, Jing Li, Ruili Qi, Yu Zeng, Xufen Wang, Wei Li, Hongjun Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title | Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title_full | Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title_fullStr | Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title_full_unstemmed | Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title_short | Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma |
title_sort | quantitative assessment of hypovascular component in arterial phase to help the discrimination of combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885771/ https://www.ncbi.nlm.nih.gov/pubmed/36727035 http://dx.doi.org/10.2147/JHC.S390820 |
work_keys_str_mv | AT yangxue quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT changjing quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT liruili quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT qiyu quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT zengxufen quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT wangwei quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma AT lihongjun quantitativeassessmentofhypovascularcomponentinarterialphasetohelpthediscriminationofcombinedhepatocellularcholangiocarcinomaandhepatocellularcarcinoma |